- Home
- RLTY vs ACIU Comparison
RLTY vs ACIU Comparison
Compare RLTY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- ACIU
- Stock Information
- Founded
- RLTY 2022
- ACIU 2003
- Country
- RLTY United States
- ACIU Switzerland
- Employees
- RLTY N/A
- ACIU N/A
- Industry
- RLTY Investment Managers
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- ACIU Health Care
- Exchange
- RLTY Nasdaq
- ACIU Nasdaq
- Market Cap
- RLTY 255.0M
- ACIU 213.3M
- IPO Year
- RLTY N/A
- ACIU 2016
- Fundamental
- Price
- RLTY $15.47
- ACIU $2.46
- Analyst Decision
- RLTY
- ACIU Strong Buy
- Analyst Count
- RLTY 0
- ACIU 2
- Target Price
- RLTY N/A
- ACIU $10.00
- AVG Volume (30 Days)
- RLTY 86.7K
- ACIU 136.3K
- Earning Date
- RLTY 01-01-0001
- ACIU 11-04-2025
- Dividend Yield
- RLTY 9.35%
- ACIU N/A
- EPS Growth
- RLTY N/A
- ACIU N/A
- EPS
- RLTY N/A
- ACIU N/A
- Revenue
- RLTY N/A
- ACIU $36,362,036.00
- Revenue This Year
- RLTY N/A
- ACIU N/A
- Revenue Next Year
- RLTY N/A
- ACIU $1,022.98
- P/E Ratio
- RLTY N/A
- ACIU N/A
- Revenue Growth
- RLTY N/A
- ACIU 86.71
- 52 Week Low
- RLTY $11.38
- ACIU $1.43
- 52 Week High
- RLTY $14.60
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- RLTY 47.93
- ACIU 60.92
- Support Level
- RLTY $15.42
- ACIU $2.12
- Resistance Level
- RLTY $15.83
- ACIU $2.35
- Average True Range (ATR)
- RLTY 0.17
- ACIU 0.14
- MACD
- RLTY -0.01
- ACIU 0.04
- Stochastic Oscillator
- RLTY 13.35
- ACIU 76.79
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.